New Single-Dose flu drug shows promise in kids trial
NCT ID NCT07095257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new flu medicine called ZX-7101A in 169 children aged 2 to 11. The medicine was given as a single oral dose, and researchers compared it to a standard 5-day treatment (oseltamivir). The main goal was to check safety and how well it relieved flu symptoms. The trial is complete, but full results are not yet available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ZX-7101A (an antiviral drug for influenza)
What this could lead to
If successful, ZX-7101A could offer a new single-dose treatment option for children with the flu, potentially simplifying care compared to current multi-day regimens.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The drug may not prove safer or more effective than existing treatments like oseltamivir, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY VIRAL INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
-
West China Second University Hospital, Sichuan University
Chengdu, Sichuan, China